Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial

• Chaoying Hu,

  Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China

  ⨯
• Jingying Jia ,

  * E-mail: jyjia@shxh-centerlab.com

  Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China

  ⨯
• Kelly Dong,

  Affiliation PTS China, GSK R&D, Shanghai, China

  ⨯
• Linda Luo,

  Affiliation Statistics, Program and Data Management, GSK R&D, Shanghai, China

  ⨯
• Kai Wu,

  Affiliation Clinical Pharmacology Modelling & Simulation, GSK R&D, Shanghai, China

  ⨯
• Rashmi Mehta,

  Affiliation Clinical Pharmacology Modelling & Simulation, GSK R&D, Research Triangle Park, NC, United States of America

  ⨯
• Jack Peng,

  Affiliation Statistics, Program and Data Management, GSK R&D, Shanghai, China

  ⨯
• Yan Ren,

  Affiliation Clinical Pharmacology Modelling & Simulation, GSK R&D, Shanghai, China

  ⨯
• Annette Gross,

  Affiliation Clinical Pharmacology Modelling & Simulation, GSK R&D, Ermington, Australia

  ⨯
• Hui Yu

  Affiliation Clinical Medicine Development, GSK R&D, Shanghai, China

  ⨯